Estudo retrospectivo de lesões em baços de caninos esplenectomizados: 179 casos

Abstract

Alterações de tamanho e forma em baços são frequentemente identificadas em cães e esplenectomia é medida terapêutica usual. Esse trabalho inclui as alterações detectadas em amostras de baços de cães esplenectomizados. Os casos foram avaliados quanto aos dados gerais, clínicos e patológicos. De um total de 9.085 amostras de tecidos caninos, 179 (2%) foram provenientes de baços de cães com esplenectomia total. A idade média dos cães foi 9,9 anos. Do total analisado, obteve-se 173 diagnósticos conclusivos, dos quais 120 (69,3%) corresponderam a doenças neoplásicas e, 53 (30,6%), doenças não neoplásicas. Dentre os diagnósticos neoplásicos, 92,5% (111/120) eram neoplasmas malignos e, 7,5% (9/120), benignos. As principais alterações identificadas foram hemangiossarcoma 44,1% (79/179), hiperplasia linfoide nodular 20,1% (36/179), fibrossarcoma 10,6% (19/179), hemangioma 3,9% (7/179) e doenças hemolíticas imunomediadas 3,9% (7/179), além de metástases de diferentes neoplasias 3,3% (6/179).

Gross changes in spleen size and shape are frequently recognized in dogs, and splenectomy is the usual measure adopted in such cases. This study includes the changes observed in spleen samples excised from dogs. Cases were evaluated on the basis of general, clinical, and histopathological findings. In the 2000-2010 period, 9085 samples of canine tissues were evaluated, 179 (2%) of which were taken from total surgical spleen removal. The mean age of dogs studied was 9.9 years. A conclusive diagnosis was obtained in 173 spleen samples, of which 120 (69.3%) were neoplastic disorders and 53 (30.6%), non-neoplastic diseases. Malignant changes corresponded to 92.5% (111/120) of the neoplastic cases, and benign ones to 7.5% (9/120). The main changes observed in spleen samples were hemangiosarcoma 44.1% (79/179), nodular lymphoid hyperplasia 20.1% (36/179), fibrosarcoma 10.6% (19/179), hemangioma 3.9% (7/179), and immune-mediated hemolytic diseases 3.9% (7/179), apart of different metastatic neoplasms 3.3% (6/179).